Outsourcing-Pharma.com presents its latest round-up of the new appointments in the pharmaceutical industry, including news from Covance, NIH and EMD Serono.
Covance has named Steve Street its new global VP and general manager.
Previously, Street was VP and head of the research centres of emphasis and continuous improvement at Pfizer.
In his new role, he will take charge of Covance’s safety assessment and pharmaceutical chemistry services.
He said: "With an increasing focus on outsourcing, this is a very exciting time to transition from pharma to a contract research organisation (CRO), and I am proud to join the industry leader. I look forward to learning from and working with a talented, dedicated group of new colleagues at Covance."
The National Institutes of Health (NIH) has appointed three new members to its advisory committee on research on women's health (ACRWH).
The new members include Afaf Meleis, currently the Margaret Bond Simon Dean of Nursing at the University of Pennsylvania School of Nursing, Heidi Nelson, who is research professor of medical informatics and clinical epidemiology and of medicine at Oregon Health and Science University, and Gerson Weiss, professor and chair of the department of obstetrics and gynecology at New Jersey Medical School.
All three will help provide guidance to the director of the NIH Office of Research on Women's Health (ORWH) as part of the board.
“Their many contributions to women's health globally, nationally, and locally reflect their deep and accomplished commitment to women's health and sex differences research. They each will contribute unique perspectives to the ACRWH's mandate," said Janine Austin Clayton, acting director of ORWH.
EMD Serono has expanded its leadership team with three new appointments.
Once global head of active strategic planniong for the firm, Allene Diaz is now senior VP and head of oncology. She will be responsible for leading the commercial efforts for EMD Serono's US oncology business.
Evan Lippman, is now senior VP of neurodegenerative diseases and rheumatology. He joins from AstraZeneca where he was executive director of the Crestor brand.
And Craig Millian becomes senior VP and head of the firm’s US fertility, metabolic endocrinology and HIV franchise. He first took on the role on an interim basis earlier this year.
James Hoyes, President of EMD Serono said: “Their knowledge, experience and global perspective will strengthen EMD Serono as a leader in biopharmaceuticals in the US. Furthermore, these appointments underscore our commitment to recruiting top external talent and promoting great talent from within.”